I. Moors MD

P10 Translocation (12;22) with TEL-MN1 (ETV6-MN1) fusion transcript: a recurrent, but rare genetic abnormality in acute myeloid leukaemia: case report and review of the literature

P11 Blastic plasmacytoid dendritic cell neoplasm with skin, bone marrow and CNS involvement: a case report

Highlights in acute myeloid leukemia

SUMMARY

With the unraveling of the molecular basis of AML last year, new treatment options have arisen and new insights were established concerning disease response to therapy, its impact on prognosis and its relevance for post-remission treatment decisions.

(BELG J HEMATOL 2017;8(4):171–5)

P40 Successful initial treatment of a cytopenic AML patient with pulmonary leukemic infiltration at diagnosis

P63 Follicular dendritic cell sarcoma: report of a case and review of the literature

Exciting times in acute myeloid leukaemia: highlights from EHA 2016

Summary

The state of the art in acute myeloid leukaemia (AML) in 2016 is changing dramatically. This is the result of the availability of new techniques for genome sequencing leading to understanding of the AML ontogeny at the molecular level, redefining minimal residual disease status in daily practice, the optimised use of induction and post-remission strategies and the introduction of many novel agents. Hopefully this will ultimately lead to the long expected improvement in survival for our individual patients.

(BELG J HEMATOL 2016;7(4):137–42)

Improving care for critically ill haematological patients in the ICU: a modern perspective

Summary

Outcome of critically ill haematological patients in the intensive care unit has substantially improved during the past decades, with current estimates for intensive care unit survival of 70–75% and one-year survival of 40–45%. Based on new insights, the approach towards critically ill haematological patients is changing, with a focus on early recognition of deteriorating patients in the ward and early referral to the intensive care unit when necessary. Broad admission policies should become the standard, with regular re-assessment of the level of care administered, relative to survival expectations and burden for the patient and family. Close collaboration and communication between attending intensivists and referring haematologists with complementary skills is essential to provide good quality of care, be it either achieving short- and long-term survival and good quality of life, or timely withdrawal of aggressive therapy and institution of appropriate comfort care.

(BELG J HEMATOL 2016; 7(3):112–7)